Selank and Short Peptides of the Tuftsin Family in the Regulation of Adaptive Behavior in Stress
Seredenin SB, Gudasheva TA, Antipova TA, Povarnina PY
Russian Journal of Bioorganic Chemistry · Vol. 42(3) · pp. 243–252 · 2016
Investigation of Selank's anxiolytic and nootropic mechanisms, demonstrating modulation of GABA-A receptors and upregulation of BDNF. Shows significant reduction in anxiety-like behavior without sedation or dependence, establishing Selank as a non-addictive anxiolytic with cognitive-enhancing properties.
Citation
Key Findings
Selank modulates GABA-A receptor activity, producing anxiolytic effects without sedation
Upregulates BDNF expression in the hippocampus and prefrontal cortex
Reduces anxiety-like behavior in multiple validated animal models
No tolerance, dependence, or withdrawal observed with chronic administration
Enhances working memory and cognitive flexibility in stressed animals
Methodology
Behavioral pharmacology studies using elevated plus maze, open field, and Morris water maze. Receptor binding assays and gene expression analysis.
Limitations
Primarily animal data; human clinical trials limited to Russian studies. Long-term safety data in humans sparse.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Semax Stimulates BDNF Expression in the Rat Brain and Exerts Neuroprotective Eff…
2006 · Moderate Evidence
Selank and Anxiety: Results of a Phase III Clinical Trial for Generalized Anxiet…
2010 · Strong Evidence
Semax, an ACTH(4-10) Analogue, Reduces Ischemic Damage and Promotes Neurological…
2019 · Strong Evidence
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) Produces Robust Cognitive En…
2013 · Moderate Evidence
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment